Challenge by API suppliers to SAMR decision likely to see more hearings in Beijing court
A Beijing court is likely to hold further hearings on legal challenges by suppliers of active pharmaceutical ingredients to a decision by the country’s top competition regulator to impose record antitrust penalties...To view the full article, register now.
Already a subscriber? Click here to view full article